Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting - humulin m3 - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - solution for injection - 100 iu/ml - insulins and analogues for injection, fast-acting - humulin s - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - solution for injection - 100 iu/ml - insulins and analogues for injection, fast-acting - humulin s - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

novo nordisk - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - novolin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. novolin n is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations diseas

Malta - inglise - Malta Medicines Authority

eli lilly & co. limited - insulin human (rdna) - suspension for injection - insulin human (rdna) 100 iu - drugs used in diabetes

Malta - inglise - Malta Medicines Authority

eli lilly & co. limited - insulin human (rdna) - solution for injection - insulin human (rdna) 100 iu - drugs used in diabetes

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - suspension for injection in cartridge - 100 international unit(s)/millilitre - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting; insulin (human)

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - suspension for injection - 100 international unit(s)/millilitre - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting; insulin (human)

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - suspension for injection - 100 international unit(s)/millilitre - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting; insulin (human)

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - solution for injection in vial - 100 international unit(s)/millilitre - insulins and analogues for injection, fast-acting; insulin (human)